Table 5.
Univariate associations between demographic, clinical and GA variables and RDI < 85%
| RDI ≥ 85% (N = 123) |
RDI < 85% (N = 36) |
OR (95% CI) | P values | |
|---|---|---|---|---|
| Continuous variables | ||||
| Age (per year) | 56.7 (11.20) | 64.2 (11.78) | 1.06 (1.02–1.10) | 0.001 |
| BMI | 29.3 (6.06) | 30.4 (7.07) | 1.03 (0.97–1.09) | 0.363 |
| BSA | 1.6 (0.13) | 1.6 (0.15) | 1.00 (0.06– 5.72) | 0.999 |
| Number of comorbidities | 1.3 (1.57) | 2.3 (2.21) | 1.30 (1.06–1.59) | 0.01 |
| ADL (MOS physical health) | 82.0 (21.30) | 70.4 (24.99) | 0.98 (0.96–0.99) | 0.009 |
| IADL | 12.4 (2.84) | 11.9 (2.93) | 0.95 (0.84–1.07) | 0.407 |
| TUG | 9.7 (2.23) | 9.9 (2.19) | 1.04 (0.88–1.22) | 0.681 |
| Patient self-rated KPS | 90.6 (12.30) | 87.2 (15.97) | 0.98 (0.96–1.01) | 0.185 |
| Physician-rated KPS | 95.0 (5.34) | 93.5 (7.34) | 0.96 (0.90–1.02) | 0.184 |
| Number of falls | ||||
| 0 | 98 (79.0%) | 26 (21.0%) | 1.00 | |
| 1+ | 23 (69.7%) | 10 (30.3%) | 1.64 (0.69–3.87) | 0.26 |
| Categorical variables | ||||
| Race | ||||
| Hispanic | 33 (82.5%) | 7 (17.5%) | 1.00 | |
| Non-Hispanic white | 63 (78.8%) | 17 (21.3%) | 1.27 (0.48–3.38) | 0.63 |
| Asian | 10 (66.7%) | 5 (33.3%) | 2.36 (0.61–9.08) | 0.21 |
| African-American | 13 (76.5%) | 4 (23.5%) | 1.45 (0.36–5.80) | 0.60 |
| Others | 3 (50.0%) | 3 (50.0%) | 4.71 (0.78–28.41) | 0.09 |
| Missing | 1 | |||
| ER–PR, HER-2 status | ||||
| ER+ or PR+, HER2- | 83 (78.3%) | 23 (21.7%) | 1.00 | |
| HER2+ | 17 (68.0%) | 8 (32.0%) | 1.70 (0.65–4.43) | 0.28 |
| ER- PR- HER2- | 23 (82.1%) | 5 (17.9%) | 0.7 8 (0.27–2.29) | 0.66 |
| Stage | ||||
| Stage I | 27 (79.4%) | 7 (20.6%) | 1.00 | |
| Stage II | 65 (73.9%) | 23 (26.1%) | 1.36 (0.52–3.56) | 0.52 |
| Stage III | 31 (83.8%) | 6 (16.2%) | 0.75 (0.22–2.49) | 0.63 |
| Chemotherapy regimen | ||||
| AC-T | 46 (82.1%) | 10 (17.9%) | 1.00 | |
| TC | 51 (86.4%) | 8 (13.6%) | 0.72 (0.26–1.98) | 0.53 |
| AC-TH | 7 (63.6%) | 4 (36.4%) | 2.63 (0.64–10.72) | 0.18 |
| TCH | 8 (72.7%) | 3 (27.3%) | 1.73 (0.39–7.68) | 0.47 |
| Sequential A-T-C | 4 (40%) | 6 (60%) | 6.90 (1.64–29.06) | 0.009 |
| Other non-HER2-targeted therapy | 4 (66.7%) | 2 (33.3%) | 2.30 (0.37–14.34) | 0.37 |
| Other HER-2-targeted therapy | 3 (50%) | 3 (50%) | 4.60 (0.81–26.22) | 0.09 |
| Anthracycline-containing regimen | ||||
| No | 61 (81.3%) | 14 (18.7%) | 1.00 | |
| Yes | 62 (73.8%) | 22 (26.2%) | 1.55 (0.72–3.30) | 0.26 |
Continuous variables are presented as mean (SD) and categorical variables as N (%)
GA geriatric assessment, RDI reduced dose intensity, BSA body surface area, BMI body mass index, ADL Activities of Daily Living, MOS Medical Outcome Study Physical Heath Scale, IADL Instrumental Activities of Daily Living, TUG Timed Up and Go, KPS Karnofsky Performance Status, TC docetaxel plus cyclophosphamide, AC-T doxorubicin plus cyclophosphamide followed by paclitaxel, TCH docetaxel, carboplatin and trastuzumab, AC-TH doxorubicin plus cyclophosphamide followed by paclitaxel plus trastuzumab, A-T-C sequential doxorubicin, paclitaxel and cyclophosphamide